Early treatment of severe aortic stenosis: do we need to wait? - EuroPCR 2025 скачать в хорошем качестве

Early treatment of severe aortic stenosis: do we need to wait? - EuroPCR 2025

In this #europcr 2025 round table, Rahul Sharma and Darren Walters explore the growing momentum behind early treatment for aortic stenosis (AS). The EARLY TAVR trial compared transcatheter aortic valve replacement (TAVR) with clinical surveillance in patients with severe asymptomatic AS at low surgical risk. Results showed a significant reduction in unplanned hospitalisations with TAVR, confirming both the safety and effectiveness of early intervention. Beyond the trial, the discussion touches on broader consequences of delayed treatment—longer hospital stays, increased complications, and prolonged recovery—all with potential cost implications. How is acute valve syndrome currently managed in the US? What about in Australia? With strong clinical evidence now available, postponing treatment may lead to worse outcomes. The key message: once severe AS is identified, make early plans for treatment. It’s not only better for the patient—it makes clinical and economic sense. Hit play to explore the full conversation! Supported by Edwards Lifesciences More videos on PCRonline: https://www.pcronline.com/Cases-resou... #aorticstenosis, #tavr, #tavi, #acutevalvesyndrome, #cost, #earlyintervention, #asymptomatic